In this article, we are going to take a look at where Viatris Inc. (NASDAQ:VTRS) stands against the other large-cap stocks. The big and large-cap stocks have spearheaded the rally in the past two ...

Viatris (VTRS) came out with quarterly earnings of $0.54 per share, missing the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.61 per share a year ago. These figures ...

PITTSBURGH, Feb. 27, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on February 24, 2025, its Board of Directors approved a 2025 dividend policy of 48 cents ($0.48 ...

CANONSBURG, Pa. (AP) — CANONSBURG, Pa. (AP) — Viatris Inc (VTRS) on Thursday reported a loss of $516.5 million in its fourth quarter. The Canonsburg, Pennsylvania-based company said it had a ...

Viatris (NASDAQ:VTRS) is scheduled to announce Q4 earnings results on Thursday, February 27th, before market open. SA analyses from early this year have ranged from cautious to optimistic ...

Medication company Viatris (NASDAQ:VTRS) will be reporting results tomorrow before market open. Here’s what to expect. Viatris beat analysts’ revenue expectations by 1% last quarter ...

With the latest hopes of licensing its hypertension drug Tryvio falling through, Idorsia has moved to claw back $100 million in upcoming development costs from a separate deal with Viatris.

India's Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of drugs from Viatris, the parent of its longstanding partner Mylan, which will boost its ...

Solara Active Pharma Sciences Limited has announced the appointment of Sandeep Rao as an Additional Director - Managing Director (MD) and Chief Executive Officer (CEO) on the Board of Directors of the ...

Despite operational successes, Viatris faced a significant 71% drop in GAAP net earnings due to international market pressures. Viatris delivered a mixed quarter, topping earnings expectations but ...